NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

More From The Market Online
Heart scans using Ventripoint Diagnostic's VMS+ technology

Ventripoint broadens access to AI cardiac imaging

Ventripoint (TSXV:VPT) is expanding access to its AI-powered cardiac imaging platform to help hospitals adopt the it without large costs.

Cannabis microcap posts potent Q2 results

MediPharm Labs (TSX:LABS), a cannabis-focused pharma company, elevated into positive net income in Q2 2026.
Eli Lilly widens its lead over Novo Nordisk as demand for weight-loss drugs drives higher revenue

Weight-loss drug boom widens Lilly’s lead over Novo

Eli Lilly’s revenue surged 48 per cent as Mounjaro and Zepbound widened its commercial lead over rival Novo Nordisk.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.